[Home](https://github.com/mm80843/T3.5/blob/pages/index.md) >> Class: [Risk](https://github.com/mm80843/T3.5/tree/pages/docs/Risk/index.md) >> Individual ID:PBN__Risk_8686 

# __Prolonged maintenance of non-pharmaceutical interventions npis and drugs until a vaccine is available.__

## Articles mentionning the risk

* [Ferguson_report_2020](https://github.com/mm80843/T3.5/blob/pages/Article/PBN__Article_469.md)

## Mitigations of this risk

* [Investment in research and development of effective vaccines and treatments for prolonged use.](https://github.com/mm80843/T3.5/blob/pages/Mitigation/PBN__Mitigation_10579.md)

## Name of the risk

Challenges in sustaining NPIs and limited effectiveness of initial vaccines.

## People affected by this risk

* [And pharmaceutical companies](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_2.md)
* [Healthcare professionals](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_32.md)
* [Researchers](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_7188.md)

## Stakeholders who can mitigate this risk

* [And pharmaceutical companies](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_880.md)
* [Government health agencies](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_413.md)
* [Research institutions](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_7188.md)

## Technologies linked to the risk

* [Vaccine development and targeted treatment options](https://github.com/mm80843/T3.5/blob/pages/Technology/PBN__Technology_10398.md)

## This Risk belongs to this RiskGroup

* [Public health risks](https://github.com/mm80843/T3.5/blob/pages/RiskGroup/PBN__RiskGroup_3.md)

## This Risk belongs to this RiskSubgroup

* [Failure to implement preventive measures](https://github.com/mm80843/T3.5/blob/pages/RiskSubgroup/PBN__RiskSubgroup_12.md)

